Effect of marihuana on intraocular and blood pressure in glaucoma
Ophthalmology, March 1980, Vol. 87, No. 3, pp. 222-228.
John C. Merritt, MD, William J. Crawford, PhD, Paul C. Alexander, MD, Alfred L.
Anduze, MD, Solomon S. Gelbart, MD
Abstract: Marihuana inhalation was accompanied by increased heart rate and decreased intraocular and blood pressure in 18 subjects with heterogenous glaucomas. The hypotensive effects appeared in 60 to 90 minutes as the decrease in intraocular pressure (IOP) appeared to follow the decrease in blood pressure. In addition to any local effect, the mechanism of lowered IOP may also involve the decreased pressure perfusing the ciliary body vasculature as a result of the peripheral vasodilatory properties of marihuana. Postural hypotension, tachycardia, palpitations, and alterations in mental status occurred with such frequency as to mitigate against the routine used in the general glaucoma population. Our data indicate that further research should be directed to local means of delivering the ocular hypotensive cannabinoid to the glaucomatous eye. [Key words: blood pressure, glaucoma, heart rate, intraocular pressure, marihuana, delta-9-tetrahydrocannabinol.] Ophthalmology 87: 222-228, 1980
In 1971, Hepler (1) observed that marihuana smoking was accompanied by decreases in ocular tension in normal males. Later Lockhart et al (2) demonstrated an ocular hupotensive effect in Jamaicans with raised intraocular tension. These ocular effects, although of potential therapeutic benefit, have not been fully documented. Our study investigates the effect of marihuana inhalation on the intraocular pressure in various forms of glaucoma.
MATERIAL AND METHODS
The patients were attending the glaucoma clinic at Howard University Hospital, Washington, DC. Those with evidence of cardiac, neurologic, or psychiatric dys-function were excluded, as were all women in the child-bearing years. After obtaining informed consent, 18 glaucoma patients (31 eyes) were selected for this study. Eight were hypertensive, four diabetic, and one asthmatic. Forty operative procedures had been performed on 17 eyes of 11 patients (Table 1). The visual acuities in the 31 glaucoma eyes are shown in Fig. 1. Nine patients had used marihuana at least once, while the remaining nine patients had not.
The marihuana cigarettes were a blend of Mexican varieties grown at the Research Institute for Pharmaceutical Studies at the University of Mississippi and made available through the National Institute on Drug Abuse, Rockville, MD. Each 900 mg marihuana cigarette contained approximately 2% delta-9-tetrahydrocannabinol by weight. Placebo therapy consisted of marihuana cigarettes that had the alcohol extractable cannabinoids removed leaving essentially a sugar and cellulose residue. Placebo cigarettes retained the same characteristic smell and taste as natural marihuana.
Glaucoma medications were discontinued in each patient 48 hours prior to testing. Initially blood pressure (BP) and heart rate (HR) were measured every five minutes while patients were sitting quietly for 15 to 20 minutes for baseline values. Intraocular pressures were then measured with a Goldmann applanation tonometer mounted onto a Haag-Streit slit lamp. One cigarette (placebo or marihuana randomly determined) was smoked over 10 to 20 minutes and the blood pressure (BP), heart rate (HR), and intraocular pressure (IOP) were measured at 15, 30, 60, 90, 120, 150, 180, and 240 minutes. Our results represent the mean + standard error of the 31 glaucoma eyes. Statistical significance for these data was selected at P <0.05 (paired t-test).
Marihuana inhalation was invariably accompanied by significant increases in the heart rate. This tachycardia was present within two to three minutes and was maximum (X=123.0 +3,4 beats/minute) at 15 minutes. Heart rates returned to control values within 90 to 120 minutes. Insignificant changes in heart rate occurred after inhalation of placebo (Fig 2). The IOP decreased 4.1 +1.5 mm Hg within the first 30 minutes after inhalation. The maximum decrease of 6.6 + 1.5 mm Hg occurred at 90 minutes. There was no difference in pressure-lowering effects in those individuals whose angles were closed by synechiae when compared to those with open angle glaucoma. Control IOP was usually reached in four hours, although a longer hypotensive effect was demonstrable in several subjects. Insignificant changes in IOP occurred after placebo therapy (Fig 3). The systolic blood pressure was decreased (X= 11.4 + 3.0 mm Hg) and diastolic BP (X= 5.1 + 1.0 mm Hg) 60 minutes after marihuana therapy. In several patients the maximum decrease in blood pressure occurred within 10 to 15 minutes and was accompanied by postural hypotension in five cases. Blood pressures were not altered after placebo therapy (Fig 4).
Table 2 lists the side effects observed after marihuana therapy in 18 subjects. Postural hypotension, occurring in five subjects, was the most serious complication encountered.
Case 1. The patient is a 28 year-old man who had never used marihuana. The visual acuity in the normal right eye was 20/15 and light perception in the left eye. Poor visual function in left eye was the result of a tractional retinal detachment, band keratopathy and glaucoma secondary to complete angle closure by a fibrovascular membrane. The IOP varied from 40 to 50 mm Hg on epinephrine 2%, diamox 500 mg twice daily, and previous cryotherapy. The subject was tested with marihuana seven days after receiving his last glaucoma medication. He successfully smoked a 900 mg cigarette in the sitting position over 10 to 15 minutes. Ten minutes after completion, the heart rate fell to 60 beats/minute with the blood pressure becoming inaudible. He became pale, cold, and sweaty as a result of the sudden decrease in blood pressure. During this period the IOP was 1 to 2 mm Hg in the right eye and 16 mm Hg in the left eye. The subject was immediately placed in the reclining position with the blood pressure rising to 110 mm Hg and IOP increased to 5 mm Hg in the right eye and 41 mm Hg in the left eye as measured with a hand-held applanation tonometer (Fig ). Case 2. The patient is a 31 year old man whose glaucoma stemmed from multiple surgical procedures for primary congenital glaucoma. The visual acuities were bare light perception in the right eye and counting fingers at two to three feet in the temporal field in the left eye. Previous medical therapy included timolol maleate 0.5% in both eyes twice daily, epinephrine 2% in both eyes twice daily, and pilocarpine 6% in the left eye four times a day. Carbonic anhydrase inhibitors were associated with kidney stones and the patient admitted that he had become a frequent (daily) user of marihuana for the past five to six years. On test day 1, he smoked a 900 mg marihuana cigarette over a 10-minute period. There were insignificant changes in IOP and virtually no change in blood pressure (Fig ^). Because of this poor response, and his previous experience with marihuana, he was tested on another day with two marihuana cigarettes which he inhaled over 25 minutes in the sitting position. Ten minutes after completion, he became nauseous, light-headed, cold, sweaty, and his blood pressure became inaudible. The heart rate decreased to 60 beats/minute and the IOP fell to 14 mm Hg (right eye) and 3 mm Hg (left eye). The subject was placed in the reclining position with a resulting rise in both the blood pressure and intraocular pressure (Fig 7).
Our study verifies that marihuana lowers both intraocular pressure and blood pressure in a heterogenous glaucoma population. The magnitude of these hypotensive effects depends on the initial pressure levels, as greater decreases in BP and IOP were evidenced in subjects with essential hypertension after single dose administration of marihuana. (4,5) The exact mechanisms by which cannabinoids effect ocular tension in man are poorly understood. In rabbits, topical (6) and intravenous (7,8) THC alter aqueous dynamics primarily through the central nervous system although intact peripheral adrenergic receptors are necessary for the full expression of the THC's effect. Intravenous delta-9-THC in rabbits with unilateral superior cervical ganglionectomy causes a 25% pressure reduction in the normal eye, with a significantly reduced effect in the eye on the side of the ganglionectomy. Similarly the beta adrenergic blockers, propranolol and sotalol, attenuate the THC pressure-lowering effect while the alpha blockers (phentolamine and Regitine) have been reported to inhibit the THC-induced increase in total outflow facility by 25% in rabbits. (9) Obvious species differences and lack of pharmacologic evidence for adrenergic receptors in the human eye preclude meaningful comparisons with the present study.
In addition to any local effect, the systemic effects of marihuana must be considered. Acute alterations in systolic blood pressure, a major modulator of IOP, (10-12) could account for the directional changes observed in IOP, as was documented in the two subjects described with postural hypotension. The marihuana-induced tachycardia may result from stimulation of beta adrenergic receptors in the heart. Although this tachycardia has been attenuated by propranolol in normal males, (13-16) Benowitz et al (17) have shown that delta-9-THC exerts both a beta stimulatory and parasympathetic inhibitory effect on the heart. Pretreatment of marihuana-experienced males with atropine and propranolol, completely abolished the effect of Delta-9-THC on the heart rate and blood pressure. Similarly, bronchodilatory effects which occurred in one asthmatic patient after marihuana corroborated other studies (18) that suggest beta agonist properties of delta-9-THC on lungs. The observed side effects in the patients who never used marihuana were more severe than in subjects who had previously experienced these effects. Anxiety concerning the tachycardia, palpitations, and postural hypotension predominated rather than euphoria: It is because of the frequency and severity with which the untoward events occurred that marihuana inhalation is not an ideal therapeutic modality for glaucoma patients.
The authors thank Roger Grimson, PhD, UNC School of Public Health for statistical analysis of these data as well as Ms. Donna Farrow and Mrs. Betty Lloyd (Medical Illustrations) for preparation of this manuscript.
1. Hepler RS, Frank IR, Marihuana smoking and intraocular pressure, JAMA 1971: 217: 1392.
2. Lockhart AB, West ME. Lowe HIC. The potential use of Cannabis sativa in ophthalmology. West Indies Med J 1977: 26: 66-70.
3. Merritt JC, Reid LA, Smith R, Harris DF. Diurnal intraocular pressure in juvenile open angle glaucoma. Ann Ophthalmology 2979; 11: 253-60.
4. Crawford WJ, Merritt JC. Effect of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharm Biopharm 1979; 17: 191-96.
5. Crawford WJ, Alexander PC, Merritt JC, Thombs MJ. Tetrahydrocannabinol effects on elevated blood pressure in humans. Prev Med 1978; 7: 54.
6. Green K, Wynn H, Bowman KA. A comparison of topical cannabinoids on intraocular pressure. Exp Eye Res 1978; 27: 239-46.
7. Green K, Kim K. Mediation of ocular tetrahydrocannabinol effects by adrenergic nervous system. Exp Eye Res 1976; 23: 443-48.
8. Green K, Bigger JF, Kim K, Bowman K. Cannabinoid action on the eye as mediated through the central nervous system and local adrenergic activity. Exp Eye Res 1977; 24: 189-96.
9. Green K, Kim K,. Interaction of adrenergic antagonist with prostaglandin E and tetrahydrocannabinol in the eye. Invest Ophthalmol 1976; 15: 102-12.
10. Levy NS, Rawitscher R. The effect of systemic hypotension during cardiopulmonary bypass on the intraocular pressure and visual function in humans. Ann Ophthalmol 1977; 9: 1547-52.
11. Bulpitt CJ, Hodes C, Everett MG. Intraocular pressure and systemic blood pressure in the elderly. Br J Ophthalmol 1975; 59: 717-20.
12. Crawford WJ, Cothran LN, Daniels ML, Tearney RJ. Direct association of systemic and intraocular hypertension. Prev Med 1979; 8: 146.
13. Beaconsfield P, Ginsburg J, Rainsburg R. Marihuana smoking--cardiovascular effects in man with possible mechanisms. N Eng J Med 1972; 287: 209-12.
14. Martz R, Brown DJ, Forney RB, Bright TP, Kiplinger GF, Rodda BE. Propranolol antagonism of marihuana induced tachycardia. Life Sce 1972; 11: 999-1005.
15. Kanakis C, Pouget JM, Rosen KM. The effects of delta-9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade. Circulation 1976; 53: 703-07.
16. Perez-Reyes M, Lipton MA, Timmons MC, Wall ME, Brine DR, DavisKH. Pharmacology of orally administered delta-9-tetrahydrocannabinol. Clin Pharm Ther 1973; 14: 48-55.
17. Benowitz NL, Rosenberg J, Rogers W, Bachman J, Jones RT. Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: Autonomic nervous mechanisms. Clin Pharm Ther 1979; 25: 440-6.
18. Vachon L, Mikus P, Morrissey W, Fitzgerald M, Gaensler E. Bronchial effect of marihuana smoke in asthma. In: The Pharmacology of Marihuana. New York: Raven Press, 1976; 777-84.